Experimental drug duo takes on tough leukemia
NCT ID NCT05597306
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a combination of two oral drugs—bomedemstat and venetoclax—in adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The main goal is to find the safest dose and check for side effects. Up to 18 participants will take the drugs daily, and researchers will also watch for signs that the leukemia is shrinking.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bomedemstat and venetoclax
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for people with hard-to-treat acute myeloid leukemia.
- What could go wrong
- This is a very early (Phase 1) trial with only 18 participants, so it is primarily testing safety and dosing. The drug combination may not work well or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?